| # | Title | Journal | Year | Citations |
|---|
| 1 | Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study | Lancet Oncology, The | 2015 | 753 |
| 2 | Development of PI3K inhibitors: lessons learned from early clinical trials | Nature Reviews Clinical Oncology | 2013 | 694 |
| 3 | First-in-Humans Trial of an RNA Interference Therapeutic Targeting VEGF and KSP in Cancer Patients with Liver Involvement | Cancer Discovery | 2013 | 618 |
| 4 | Prognostic and Predictive Relevance of Primary Tumor Location in Patients With RAS Wild-Type Metastatic Colorectal Cancer | JAMA Oncology | 2017 | 555 |
| 5 | Dose- and Schedule-Dependent Inhibition of the Mammalian Target of Rapamycin Pathway With Everolimus: A Phase I Tumor Pharmacodynamic Study in Patients With Advanced Solid Tumors | Journal of Clinical Oncology | 2008 | 519 |
| 6 | The Oncosurgery Approach to Managing Liver Metastases from Colorectal Cancer: A Multidisciplinary International Consensus | Oncologist | 2012 | 453 |
| 7 | Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial | Lancet Oncology, The | 2020 | 297 |
| 8 | Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1–Low/Negative Recurrent or Metastatic HNSCC | JAMA Oncology | 2019 | 235 |
| 9 | CDK12 Inhibition Reverses De Novo and Acquired PARP Inhibitor Resistance in BRCA Wild-Type and Mutated Models of Triple-Negative Breast Cancer | Cell Reports | 2016 | 215 |
| 10 | Efficacy and Safety of Bevacizumab in Metastatic Colorectal Cancer: Pooled Analysis From Seven Randomized Controlled Trials | Oncologist | 2013 | 210 |
| 11 | Primary tumor sidedness has an impact on prognosis and treatment outcome in metastatic colorectal cancer: results from two randomized first-line panitumumab studies | Annals of Oncology | 2017 | 174 |
| 12 | Targeting c-MET in gastrointestinal tumours: rationale, opportunities and challenges | Nature Reviews Clinical Oncology | 2017 | 150 |
| 13 | Phase I safety, pharmacokinetic, and pharmacodynamic study of the oral phosphatidylinositol-3-kinase and mTOR inhibitor BGT226 in patients with advanced solid tumors | Annals of Oncology | 2012 | 125 |
| 14 | Prognostic Factors of Survival in a Randomized Phase III Trial (MPACT) of Weekly nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine Alone in Patients With Metastatic Pancreatic Cancer | Oncologist | 2015 | 123 |
| 15 | Toxicity as a Biomarker of Efficacy of Molecular Targeted Therapies: Focus on EGFR and VEGF Inhibiting Anticancer Drugs | Oncologist | 2011 | 117 |
| 16 | SEOM clinical guidelines for the treatment of non-small cell lung cancer (2018) | Clinical and Translational Oncology | 2019 | 110 |
| 17 | Role of Deficient DNA Mismatch Repair Status in Patients With Stage III Colon Cancer Treated With FOLFOX Adjuvant Chemotherapy | JAMA Oncology | 2018 | 104 |
| 18 | Sorafenib in metastatic thyroid cancer | Endocrine-Related Cancer | 2012 | 96 |
| 19 | Meta-analysis of individual patient safety data from six randomized, placebo-controlled trials with the antiangiogenic VEGFR2-binding monoclonal antibody ramucirumab | Annals of Oncology | 2017 | 93 |
| 20 | New clinical trial designs in the era of precision medicine | Molecular Oncology | 2019 | 89 |
| 21 | Molecular Profiling of Patients with Colorectal Cancer and Matched Targeted Therapy in Phase I Clinical Trials | Molecular Cancer Therapeutics | 2012 | 77 |
| 22 | The anti-cancer drug ABTL0812 induces ER stress-mediated cytotoxic autophagy by increasing dihydroceramide levels in cancer cells | Autophagy | 2021 | 72 |
| 23 | Fluorescence In Situ Hybridization and Immunohistochemistry as Diagnostic Methods for ALK Positive Non-Small Cell Lung Cancer Patients | PLoS ONE | 2013 | 68 |
| 24 | Innovations therapy: mammalian target of rapamycin (mTOR) inhibitors for the treatment of neuroendocrine tumors | Cancer and Metastasis Reviews | 2011 | 67 |
| 25 | Drug development to overcome resistance to EGFR inhibitors in lung and colorectal cancer | Molecular Oncology | 2012 | 66 |
| 26 | Opinion about reproductive decision making among individuals undergoing BRCA1/2 genetic testing in a multicentre Spanish cohort | Human Reproduction | 2008 | 61 |
| 27 | Association of Prognostic Value of Primary Tumor Location in Stage III Colon Cancer WithRASandBRAFMutational Status | JAMA Oncology | 2018 | 55 |
| 28 | BRAF as a Target for Cancer Therapy | Anti-Cancer Agents in Medicinal Chemistry | 2011 | 53 |
| 29 | Vandetanib in Advanced Medullary Thyroid Cancer: Review of Adverse Event Management Strategies | Advances in Therapy | 2013 | 53 |
| 30 | Nintedanib for the treatment of patients with refractory metastatic colorectal cancer (LUME-Colon 1): a phase III, international, randomized, placebo-controlled study | Annals of Oncology | 2018 | 47 |
| 31 | Selecting Patients with Ovarian Cancer for Germline BRCA Mutation Testing: Findings from Guidelines and a Systematic Literature Review | Advances in Therapy | 2016 | 46 |
| 32 | Molecular Predictors of Response to Chemotherapy in Colorectal Cancer | Cancer Journal (Sudbury, Mass ) | 2011 | 40 |
| 33 | Bone health in a prospective cohort of postmenopausal women receiving aromatase inhibitors for early breast cancer | Breast | 2012 | 40 |
| 34 | Efficacy and safety results from GEICO 1205, a randomized phase II trial of neoadjuvant chemotherapy with or without bevacizumab for advanced epithelial ovarian cancer | International Journal of Gynecological Cancer | 2019 | 39 |
| 35 | Prognostic and predictive roles for circulating biomarkers in gastrointestinal cancer | Future Oncology | 2011 | 38 |
| 36 | Application of Monoclonal Antibodies as Cancer Therapy in Solid Tumors | Current Clinical Pharmacology | 2012 | 36 |
| 37 | HER2 in high-risk rectal cancer patients treated in EXPERT-C, a randomized phase II trial of neoadjuvant capecitabine and oxaliplatin (CAPOX) and chemoradiotherapy (CRT) with or without cetuximab | Annals of Oncology | 2013 | 32 |
| 38 | SEOM clinical guideline of venous thromboembolism (VTE) and cancer (2019) | Clinical and Translational Oncology | 2020 | 32 |
| 39 | Axitinib treatment in advanced RAI-resistant differentiated thyroid cancer (DTC) and refractory medullary thyroid cancer (MTC) | European Journal of Endocrinology | 2017 | 30 |
| 40 | A Shining Light in the Darkness for the Treatment of Pancreatic Neuroendocrine Tumors | Cancer Discovery | 2011 | 26 |
| 41 | SPROUTY2 is a β-catenin and FOXO3a target gene indicative of poor prognosis in colon cancer | Oncogene | 2014 | 26 |
| 42 | Phase I Pharmacokinetic and Pharmacodynamic Study of Weekly 1-Hour and 24-Hour Infusion BMS-214662, a Farnesyltransferase Inhibitor, in Patients With Advanced Solid Tumors | Journal of Clinical Oncology | 2005 | 25 |
| 43 | Evaluation of the efficacy and safety of lanreotide in combination with targeted therapies in patients with neuroendocrine tumours in clinical practice: a retrospective cross-sectional analysis | BMC Cancer | 2015 | 25 |
| 44 | Development of Molecular Biomarkers in Individualized Treatment of Colorectal Cancer | Clinical Colorectal Cancer | 2011 | 24 |
| 45 | Proliferation signal inhibitors and post‐transplant malignancies in heart transplantation: practical clinical management questions | Clinical Transplantation | 2011 | 24 |
| 46 | Optimal design of trials to demonstrate the utility of genomically‐guided therapy: Putting Precision Cancer Medicine to the test | Molecular Oncology | 2015 | 24 |
| 47 | miRNA-197 and miRNA-184 are associated with brain metastasis in EGFR-mutant lung cancers | Clinical and Translational Oncology | 2016 | 24 |
| 48 | Non-inferiority multicenter prospective randomized controlled study of rectal cancer T2–T3s (superficial) N0, M0 undergoing neoadjuvant treatment and local excision (TEM) vs total mesorectal excision (TME) | International Journal of Colorectal Disease | 2018 | 24 |
| 49 | A precision approach to tumour treatment | Nature | 2017 | 23 |
| 50 | Prognostic Value of Methylator Phenotype in Stage III Colon Cancer Treated with Oxaliplatin-based Adjuvant Chemotherapy | Clinical Cancer Research | 2018 | 23 |
